Pacific Biosciences (PACB) Shares Surge +73% in 30 Days on Partnership Momentum
Key Takeaways
- Pacific Biosciences (PACB) shares climbed roughly 73% over the last 30 days, rising from a closing price of $1.355 on August 31, 2026 to approximately $2.345 in late September.
- The rally was driven by a series of partnership and contract announcements tied to PacBio's HiFi long-read sequencing technology, including the Sampled–U.S. Department of Veterans Affairs agreement.
- Over the last quarter, the stock advanced about 40%, though the path was volatile, with shares trading near $1.07–$1.11 in mid-August after second-quarter results and lowered guidance.
- Key catalysts include the SPRQ-Nx chemistry rollout, the DNAstack rare-disease data collaboration, and the Basecamp Research "Trillion Gene Atlas" initiative.
- Analyst sentiment remains mixed, with a consensus Hold rating and an average price target near $2.12 as of late September.
Pacific Biosciences (PACB) Company Overview and Market Position
Pacific Biosciences of California, Inc. (PACB), widely known as PacBio, designs and manufactures advanced genetic sequencing systems used by researchers and clinical laboratories. Its core offering, HiFi long-read sequencing, provides highly accurate, comprehensive views of genomes and is applied across human genetics, oncology, infectious disease, plant and animal sciences, and microbiology.
The company's product lineup includes the high-throughput Revio system and the more accessible Vega platform, complemented by consumables such as the PureTarget kit and the recently launched SPRQ-Nx chemistry. PacBio competes in the broader genomics and life sciences tools market, positioning HiFi sequencing as a lower-cost, high-accuracy alternative that can capture complex genetic variants in a single assay. Investors follow the stock for its exposure to clinical genomics, rare-disease diagnostics, and large-scale biological data initiatives. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Pacific Biosciences (PACB) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, PACB shares gained approximately 73%, rising from a close of $1.355 on August 31, 2026 to roughly $2.345 by late September. Most of the advance occurred in the final week of the period, as shares moved from about $1.36 on September 21 to above $2.30, reflecting an acceleration in trading activity and volume.
The last quarter told a broader story of recovery. From a closing level near $1.68 at the end of June 2026, the stock declined through July and early August, bottoming near $1.07–$1.11 in mid-August after second-quarter results. From that trough, shares recovered roughly 40% over the quarter, with the bulk of gains concentrated in September as a sequence of collaborations and contract announcements reinforced the company's commercial narrative.
What Drove PACB Stock Price in the Last 30 Days
The 30-day surge was fueled primarily by verified commercial and partnership developments. In late September, genomics provider Sampled announced a five-year contract worth up to $27.1 million from the U.S. Department of Veterans Affairs to support the Million Veteran Program using PacBio Revio sequencing systems, triggering a sharp single-session gain. Earlier in the month, PacBio's collaboration with DNAstack to launch a global federated dataset of HiFi whole-genome sequencing data for rare-disease research also lifted shares.
These announcements built on the momentum of the SPRQ-Nx chemistry launch, which management has described as improving sequencing economics through multi-use SMRT cells and lower cost per genome. On the analyst front, UBS initiated coverage with a Neutral rating and a $1.35 price target in early September, while Canaccord Genuity reiterated a Buy rating. The mix of new contracts, product traction, and renewed attention to AI-linked biological data initiatives contributed to a sentiment shift despite mixed ratings.
What Drove PACB Stock Performance Over the Last Quarter
The quarter's broader narrative centered on a sharp drawdown followed by recovery. Second-quarter 2026 results reported revenue of approximately $39 million, roughly flat year over year, alongside a GAAP net loss of about $44.7 million and reduced full-year guidance. Those figures, combined with an ongoing CEO transition to Mark Van Oene and continued pressure on academic and government funding, pushed shares to multi-month lows in August.
From that low point, the recovery was driven by the rollout of SPRQ-Nx, record consumables momentum in clinical and hospital channels, and a string of high-profile collaborations, including the Basecamp Research "Trillion Gene Atlas" partnership to sequence roughly 100,000 samples. These developments reframed the investment narrative from cost-cutting and restructuring toward clinical adoption and long-read sequencing's role in large-scale biological data generation.
PACB Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors are likely to focus on PacBio's upcoming quarterly results and any updates to full-year revenue guidance, which was lowered earlier in 2026. Adoption of SPRQ-Nx and multi-use SMRT cells, instrument placement trends for Revio and Vega, and the conversion of partnerships such as the Basecamp Research and DNAstack collaborations into recurring consumables demand will be important indicators of durable growth.
Additional factors to monitor include the pace of clinical and hospital consumables growth, the recovery of academic funding, gross-margin trajectory, and progress toward the company's stated cash-flow breakeven target. Macroeconomic conditions, tariffs and supply-chain costs, and competitive developments across the sequencing industry also remain relevant. These factors are presented for informational purposes only and do not constitute a forecast or recommendation. From what I see, monitoring these elements closely helps frame the longer-term outlook.
Exploring AI Tools for Stock Analysis
In my view, supplementing traditional research with systematic signals can add useful perspective when evaluating names like PACB. I often turn to Tickeron’s AI Trading Bots for this, as the platform offers a range of automated strategies across different timeframes and risk profiles. The trending robots section provides a curated view of top-performing options, which I find helpful for identifying patterns without replacing my own due diligence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
PACB in upward trend: price rose above 50-day moving average on September 17, 2026
PACB moved above its 50-day moving average on September 17, 2026 date and that indicates a change from a downward trend to an upward trend. In 34 of 38 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 16, 2026. You may want to consider a long position or call options on PACB as a result. In 71 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for PACB just turned positive on September 15, 2026. Looking at past instances where PACB's MACD turned positive, the stock continued to rise in 34 of 47 cases over the following month. The odds of a continued upward trend are 72%.
The 10-day moving average for PACB crossed bullishly above the 50-day moving average on September 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 64%.
Following a +37.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where PACB advanced for three days, in 220 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PACB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
PACB broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. PACB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 64 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: PACB's P/B Ratio (169.492) is very high in comparison to the industry average of (10.853). P/E Ratio (355.780) is within average values for comparable stocks, (98.910). PACB's Projected Growth (PEG Ratio) (180.110) is very high in comparison to the industry average of (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.565) is also within normal values, averaging (39.828).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of sequencing system products to help scientists to resolve genetically complex problems
Industry MedicalNursingServices